Gubra Advances Obesity Pipeline as AbbVie and Boehringer Ingelheim Programs Reach Phase 2
核心洞察
Gubra (搜索) initiated the Phase 1/2a trial of GUB-UCN2 (搜索), advancing its internal R&D pipeline into clinical development during H1 2026.
Partnered obesity (搜索) programs from AbbVie (搜索) and Boehringer Ingelheim advanced to Phase 2, underscoring the value of Gubra (搜索)'s peptide discovery platform.
H1 2026 revenue fell to DKK 126.3 million from DKK 2,492.1 million a year earlier, reflecting a large one-time AbbVie (搜索) deal in the prior-year period.
Gubra (搜索) reported strong execution across its integrated business model during the first half of 2026, marked by the initiation of its GUB-UCN2 (搜索) Phase 1/2a trial, the advancement of partnered obesity (搜索) programs to Phase 2 by AbbVie (搜索) and Boehringer Ingelheim, and the launch of its new Gubra Ventures initiative.
Pipeline and Partnership Milestones
Multiple key milestones were reached during the period. Gubra (搜索) initiated the Phase 1/2a trial of GUB-UCN2 (搜索), moving its internal R&D pipeline forward. In parallel, AbbVie (搜索) and Boehringer Ingelheim advanced their partnered obesity (搜索) programs to Phase 2, reflecting continued progress across Gubra's collaboration portfolio. The company also established new strategic partnerships during the period.
Gubra (搜索) Ventures was launched to accelerate innovation and value creation, with multiple deals under evaluation and a first announcement expected soon.
Financial Performance
H1 2026 revenue was DKK 126.3 million, down from DKK 2,492.1 million in H1 2025, a decline attributable to a large one-time AbbVie (搜索) deal recorded in the prior year. Biotech revenue was DKK 30 million in H1 2026.
The group reported an EBIT loss of DKK 122.9 million, compared with a profit of DKK 2,252.2 million in H1 2025. Within this, Biotech posted an EBIT loss of DKK 120 million, while the CRO segment delivered EBIT of DKK 1.5 million.
CRO revenue grew 11% compared to H2 2025, reaching DKK 96 million, driven by improved demand and a rebound in biotech funding. The net loss for H1 2026 was DKK 110 million, with cash and equivalents of DKK 901.3 million as of June 30, 2026.
Outlook
Gubra (搜索)'s 2026 outlook remains unchanged, with CRO revenue growth expected at 0–10% and an EBIT margin of 10–15%. The company provides no revenue guidance for the Biotech segment due to the unpredictability of partnership payments. The CRO business aims for 10% annual growth in 2027, supported by an expanded model portfolio and cost discipline.